Delivered by:

  • Dr Derek Connolly (Chair), Consultant Interventional Cardiologist and Honorary Senior Clinical Lecturer at Birmingham City Hospital
  • Helen Williams FFRPS, FRPharmS, Consultant Pharmacist for Cardiovascular Disease, South-East London CCG and UCLPartners National Specialty Adviser for CVD Prevention, NHSE and I

This webinar is delivered in partnership with the Primary Care Cardiovascular Society and the Best Practice Show.


There is incontrovertible evidence that LDL cholesterol is a major risk factor in the development of atherosclerotic cardiovascular disease, which remains one of the world’s great killers.

There are now five different ways of lowering LDL cholesterol. As well as statins, we now have ezetimibe, bempedoic acid, PCSK9i monoclonal, antibodies, and now inclisiran.

We will review their usage in both primary and secondary prevention with particular reference to the new NICE cholesterol guidance which emphasises that treatments should be used in combinations to achieve target LDL values.

Identifying at risk patience and optimising levels could substantially reduce the burden of cardiovascular disease in the UK.